Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.
In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was transformed with a lambdaZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (MMGL, phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blot analysis revealed that serum anti-myomegalin antibodies (s-MMGL-Abs) were present in 43 (47%) of 91 patients, but in only one (2.2%) of 45 healthy controls. Of the 21 patients with stage I disease, 8 (38%) were sero-positive. The positive rate of s-MMGL-Abs was greater than those of other conventional tumor markers. Reverse transcription-PCR analysis suggested that alternative splicing from myomegalin variant 1 to variant 5 may explain, in part, the development of s-MMGL-Abs. Although the presence of s-MMGL-Abs was not related to any clinicopathological features of the patients, multivariate analysis indicated that the presence of s-MMGL-Abs was significantly associated with a favorable prognosis. Consequently, s-MMGL-Abs may be a useful tumor marker to diagnose and establish a prognosis in patients with esophageal SCC.
Shimada
Hideaki
H
Department of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan.
Kuboshima
Mari
M
Shiratori
Tooru
T
Nabeya
Yoshihiro
Y
Takeuchi
Atsushi
A
Takagi
Hiroaki
H
Nomura
Fumio
F
Takiguchi
Masaki
M
Ochiai
Takenori
T
Hiwasa
Takaki
T
D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000276:immunology; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D017931:DNA Primers; D018076:DNA, Complementary / Q000235:genetics; D004938:Esophageal Neoplasms / Q000235:genetics / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008869:Microtubule-Associated Proteins / Q000097:blood / Q000235:genetics* / Q000276:immunology; D008875:Middle Aged; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
D001323:Autoantibodies; D014408:Biomarkers, Tumor; D017931:DNA Primers; D018076:DNA, Complementary; D008869:Microtubule-Associated Proteins; C426025:Pde4dip protein, rat